MedTrace Logo

A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

NCT02605785 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 332

Last updated 2026-05-05

No results posted yet for this study

Summary

This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).

Conditions

Interventions

DRUG

F-18 AV 1451

Tau PET scan

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Jennifer Whitwell, PhD · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2030-01-31
Completion
2030-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02605785 on ClinicalTrials.gov